Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.62% 162.50 160.00 165.00 165.00 162.50 162.50 1,922,789 15:28:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 292

Amryt Pharma Share Discussion Threads

Showing 6526 to 6547 of 6650 messages
Chat Pages: 266  265  264  263  262  261  260  259  258  257  256  255  Older
DateSubjectAuthorDiscuss
29/3/2021
08:29
Unfortunately today's RNS hasn't generated much buying interest going by the share price Wonder what they'll make of it on Nasdaq?
papillon
29/3/2021
07:37
Theres the EMA
alphabravo321
27/3/2021
16:09
Amryt has stated in the March corporate presentation (see website) that "Q1 2021- Oleogel-S10 FDA & EMA filings" so this is not something that should be a surprise.
whatno
27/3/2021
15:49
There has clearly been an overhang. Happy to hold and see out all 2021
moorsie2
26/3/2021
22:17
"Has the overhang been cleared? Some decent sized late reported trades.. FDA Application for Filsuvez should be filed early next week.. Hopefully!" >>>>>>>>>>>>>>>>>>>>>>>>> Posted today by knowledgeable Irish based investor, Bronxville, on the lse AMYT bb. Let's hope he's correct regarding the FDA and Filsuvez.
papillon
25/3/2021
23:54
Regarding Ray Stafford's recent purchase of 300,100 shares @ £2, I wonder why he purchased the shares on the LSE and not Nasdaq? After all when AMYT listed on Nasdaq the Directors said they were in the process of transferring all of their shareholdings from the LSE to Nasdaq. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-plc-Director-Pdmr-Shareholding/84575041
papillon
25/3/2021
21:39
Whooooosh, one of my favourite words!!
bazworth
25/3/2021
21:00
The share price is drifting back to the price before we had all the positive rns throughout this month.The company is growing from strength to strength unfortunately the share price doesnt seem to reflect the progress :-(One day, one day when we least expect it we get that well deserved wooooosh
digadee
23/3/2021
23:43
free stock charts from uk.advfn.com free stock charts from uk.advfn.com God only knows where the April dates shown on the advfn charts come from. Lets hope that the bottom of the Ichimoku "cloud" acts as support on both the lse & Nasdaq charts.
papillon
23/3/2021
18:14
Paps - I have a similar story, although I have been in and out a few times since the fastnet days. You are absolutely right that anticipated news rarely moves a share price (much) - I think there has also been a change in sentiment in the US given the dive in Nasdaq listed stocks of late. Amryt is not the most exciting share but at least there don't appear to be any skeletons in the cupboard that are likely to cause a 50% overnight loss (which I have had happened with other biotechs). The news today regarding PL in the US does suggest that they have a high probability of significantly increasing revenues from Metreleptin - albeit from 2023 onwards. I'm not aware of any other drug being developed for this indication that could cause clouds on the horizon. I would hope that FDA acceptance of the Fulsivez NDA (assuming that happens) might at least generate some more enthusiasm from investors..
whatno
23/3/2021
17:22
Join the club, whatno! I've got this wrong ever since I first bought into FAST around 6 years ago, when it was basically a cash shell, thinking (and hoping) it would return it's cash to shareholders, or line up a juicy acquisition. It did neither: instead a boring and with the benefit of hindsight, a vastly over priced, company RTO'd into FAST and became AMYT! I've hung on ever since, whilst it's great hope AP101 suffered delay, after delay. Initially the RTO placing was at 24p (= 144p), but the share price has failed to perform during the almost 5 years since the RTO. Along the way Amicus's competitor to AP101 (for which Amicus paid Socioderm a lot of money) failed phase 3 and that set AMYT back and led to changes to it's AP101 phase 3 trials. Cathal Friel, who was behind FAST and the AMYT RTO, got fed up and exited AMYT and has done spectacularly well with his next biotech vehicle, ORPH, courtesy of COVID 19. However I'm still clinging on! And will continue to cling on until AP101 (or whatever they call it these days!) gets (or doesn't get) FDA approval and AMYT gets loads of dollars for selling on it's fast track approval. I live in hope! PS There's a fair bit of chart support @ circa £2. Will it hold? We'll have to wait and see.
papillon
23/3/2021
15:43
Paps - I stand corrected :-)
whatno
23/3/2021
14:33
As each day passes here I sounding more and more like Victor Meldrew.....................Unbelievable !
richpassi
23/3/2021
14:02
Funny old game!!
bazworth
23/3/2021
08:49
Great news... So it falls..
babbler
23/3/2021
08:38
I imagine this will get US investors interested. Generally, anything with FDA in the press release wakes them up.
whatno
23/3/2021
07:41
That's disappointing to have more good news, not sure if the share price can take too much more of it...
cwa1
23/3/2021
07:08
They don’t hang around, do they!
bazworth
23/3/2021
07:05
More good news
alphabravo321
22/3/2021
11:17
I've never understood why Broker's price targets exist at all as they mostly appear nonsensical a best! Would seem a complete waste of time and of the cash paying for their completion!!
bazworth
22/3/2021
10:40
I wouldn't take any notice of broker price targets, Moorsie2, especially not an share price prediction from Davy. I remember once upon a time they predicted £23 for PVR, who are currently under 5p.🤣 I recall someone posting that broker share price forecasts should be halved and then halved again! PS. Davy are currently in very hot water in Ireland for some very dodgy dealing. Definitely a broker to avoid when it comes to price predictions!
papillon
22/3/2021
10:28
I would have thought the FDA submission would wake up US investors. However, You can't ignore the risk-off change in sentiment in the US (Nasdaq) - this has had a marked effect on growth stocks.
whatno
Chat Pages: 266  265  264  263  262  261  260  259  258  257  256  255  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 15:04:29